Konstantin A Senkevich

List of Publications by Year
in descending order

45	861	623734	526287
papers	citations	14 h-index	27 g-index

60	60	60	1343
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Neuropharmacology, 2022, 202, 108822.	4.1	33
2	Genetics of Non-Motor Symptoms of Parkinsonâ€™s Disease. , 2022, , 199-211.		0
3	Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with <scp>GBA1</scp> Mutations?. Movement Disorders, 2022, 37, 1779-1781.	3.9	5
4	Genetics variants and expression of the SCARB2 gene in the pathogenesis of Parkinson's disease in Russia. Neuroscience Letters, 2021, 741, 135509.	2.1	5
5	Lack of evidence for association of UQCRC1 with Parkinson's disease in Europeans. Neurobiology of Aging, 2021, 101, 297.e1-297.e4.	3.1	7
6	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. Neurobiology of Aging, 2021, 103, 142.e1-142.e5.	3.1	11
7	P.101 Involvement of the genes related to lysosomal storage disorders in GBA-associated Parkinson's disease. European Neuropsychopharmacology, 2021, 44, S1-S2.	0.7	0
8	P.114 Contribution of the SNCA gene and genes involved in autophagy in the pathogenesis of GBA-associated parkinson's disease. European Neuropsychopharmacology, 2021, 44, S10-S11.	0.7	1
9	Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. Parkinsonism and Related Disorders, 2021, 84, 112-121.	2.2	25
10	Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. Movement Disorders, 2021, 36, 1420-1429.	3.9	108
11	No Evidence for a Causal Relationship Between Cancers and Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 801-809.	2.8	3
12	Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease. Movement Disorders, 2021, 36, 1967-1972.	3.9	3
13	Increased Î±â€Synuclein Level in <scp>CD45</scp>+ Blood Cells in Asymptomatic Carriers of <scp>GBA</scp> Mutations. Movement Disorders, 2021, 36, 1997-1998.	3.9	5
14	Fine mapping of the HLA locus in Parkinsonâ€™s disease in Europeans. Npj Parkinson's Disease, 2021, 7, 84.	5.3	31
15	Î±â€Synuclein (<scp>SNCA</scp>) <scp>A30G</scp> Mutation as a Cause of a Complex Phenotype Without Parkinsonism. Movement Disorders, 2021, 36, 2209-2212.	3.9	1
16	SORL1 mutation in a Greek family with Parkinson's disease and dementia. Annals of Clinical and Translational Neurology, 2021, 8, 1961-1969.	3.7	7
17	Glucocerebrosidase activity and transport to lysosomes in primary macrophages from patients with mutations in the GBA gene. Journal of the Neurological Sciences, 2021, 429, 119511.	0.6	0
18	Alteration of expression levels of genes involved in maintaining dopaminergic system as trigger for GBA-associated Parkinson's disease. Journal of the Neurological Sciences, 2021, 429, 119573.	0.6	0

#	Article	IF	Citations
19	Profiling the biochemical lysosomal activities in blood of patients with multiple system atrophy. Journal of the Neurological Sciences, 2021, 429, 117668.	0.6	0
20	Alteration of lysosomal enzymatic activities as risk factor of Parkinson's disease associated with mutations in the GBA gene. Journal of the Neurological Sciences, 2021, 429, 119577.	0.6	0
21	Parkinsonâ€™s Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. Acta Naturae, 2021, 13, 70-78.	1.7	6
22	P.0425 Link between multiple system atrophy and lysosomal storage disorders. European Neuropsychopharmacology, 2021, 53, S309.	0.7	0
23	P.0428 Alpha-synuclein alters expression levels of immediate early genes in Parkinson's disease associated with mutations in the GBA gene. European Neuropsychopharmacology, 2021, 53, S311-S312.	0.7	0
24	P.0881 Screening of CLN3 variants (rs146610181 and rs77595156) in patients with Parkinson's disease in Russia. European Neuropsychopharmacology, 2021, 53, S645-S646.	0.7	0
25	P.0730 Alteration of lysosomal activities associate with disturbance of alpha-synuclein protein level in blood of patients with GBA-associated parkinson's disease. European Neuropsychopharmacology, 2021, 53, S533.	0.7	0
26	Transcriptome analysis highlights common pathways between Alzheimerâ€™s disease, dementia with Lewy bodies and Parkinsonâ€™s disease. Alzheimer's and Dementia, 2021, 17, e050014.	0.8	0
27	Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics. Parkinsonism and Related Disorders, 2020, 73, 60-71.	2.2	85
28	P.359 Expression profile of genes involved in endolysosomal pathway in CD45+ blood cells as potential marker for differentiation of synucleinophaties. European Neuropsychopharmacology, 2020, 40, S208-S209.	0.7	0
29	Postural instability and neuropsychiatric disturbance in the overlapping phenotype of essential tremor and Parkinson's Disease. Neurophysiologie Clinique, 2020, 50, 489-494.	2.2	2
30	Relevance of biomarkers across different neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 56.	6.2	42
31	Plasma Cytokines Profile in Patients with Parkinsonâ€™s Disease Associated with Mutations in GBA Gene. Bulletin of Experimental Biology and Medicine, 2020, 168, 423-426.	0.8	24
32	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases courseâ€”a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20.	6.2	32
33	Plasma cytokine profile in synucleinophaties with dementia. Journal of Clinical Neuroscience, 2020, 78, 323-326.	1.5	16
34	Variants in the Niemannâ€“Pick type C gene NPC1 are not associated with Parkinson's disease. Neurobiology of Aging, 2020, 93, 143.e1-143.e4.	3.1	13
35	AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nature Communications, 2019, 10, 3094.	12.8	150
36	Human Peripheral Blood Macrophages As a Model for Studying Glucocerebrosidase Dysfunction. Cell and Tissue Biology, 2019, 13, 100-106.	0.4	6

#	Article	IF	Citations
37	Prion Properties of Alpha-Synuclein. Molecular Biology, 2019, 53, 335-341.	1.3	5
38	PDXK mutations cause polyneuropathy responsive to pyridoxal 5â€²â€phosphate supplementation. Annals of Neurology, 2019, 86, 225-240.	5.3	54
39	SNCA variants and alpha-synuclein level in CD45+ blood cells in Parkinsonâ€™s disease. Journal of the Neurological Sciences, 2018, 395, 135-140.	0.6	18
40	Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations. Movement Disorders, 2018, 33, 1325-1330.	3.9	34
41	Mutation analysis of Parkinson's disease genes in a Russian data set. Neurobiology of Aging, 2018, 71, 267.e7-267.e10.	3.1	40
42	ÐœÐÐšÐÐžÐÐÐ“Ð˜ ÐŸÐ•ÐÐ˜ÐÐ•ÐÐ˜Ð§Ð•Ð¡ÐšÐžÐ™ ÐšÐÐžÐ’Ð˜ Ð§Ð•Ð›Ð›ÐžÐ’Ð•Ð•Ðš ÐœÐžÐ”Ð•Ð›Ð¬ Ð˜Ð—Ð£Ð§Ð•ÐÐ˜Ð˜ Ð”Ð¤Ð	0.2	0
43	Oligomeric Î±-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinsonâ€™s disease. Neuroscience Letters, 2017, 636, 70-76.	2.1	61
44	SNCA alleles rs356219 and rs356165 are associated with Parkinsonâ€™s disease and increased Î±-synuclein gene expression in CD45+ blood cells. Cell and Tissue Biology, 2016, 10, 277-283.	0.4	1
45	Changes of fractional anisotropy (FA) and apparent diffusion coefficient (ADC) in the model of experimental acute hydrocephalus in rabbits. Acta Neurochirurgica, 2015, 157, 689-698.	1.7	4